Multidomain Lifestyle Intervention May Aid Cognition in APOE ε4 Carriers
THURSDAY, Jan. 25, 2018 -- A multidomain lifestyle intervention seems to be beneficial for cognition in older at-risk individuals, even among apolipoprotein E (APOE) ε4 carriers, according to a study published online Jan. 22 in JAMA Neurology.
Alina Solomon, M.D., Ph.D., from the University of Eastern Finland in Kuopio, and colleagues analyzed data from the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, in which at-risk older individuals (aged 60 to 77 years) were randomized to a multidomain intervention group (diet, exercise, cognitive training, and vascular risk management) or a control group (general healthy advice). A total of 1,109 participants were included in the analysis: 362 APOE ε4 allele carriers and 747 noncarriers.
The researchers found that for the annual neuropsychological test battery total score change, the difference between the intervention and control groups was 0.037 (95 percent confidence interval, 0.001 to 0.073) among carriers and 0.014 (95 percent confidence interval, −0.011 to 0.039) among noncarriers. There was no significant difference in the intervention effect between carriers and noncarriers (0.023; 95 percent confidence interval, −0.021 to 0.067).
"Healthy lifestyle changes may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia," the authors write. "Whether such benefits are more pronounced in APOE ε4 carriers compared with noncarriers should be further investigated."
The study was funded in part by the Novo Nordisk Foundation.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.